2013-01-09 07:33:32 -
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), announces
today
that a Master Service Agreement has been signed with Sanofi, a global and
diversified healthcare leader. This Master Service Agreement follows a
successful collaboration in ongoing development of a number of formulations
which has made and will make a material contribution to OctoPlus' 2012 and 2013
revenues. Further details on the compound and activities are not disclosed.
Mr. Jan Egberts, CEO of OctoPlus comments: "We are proud of the confidence
Sanofi has shown in our organization by signing this Agreement. It reflects the
success of our scientists and engineers who continuously develop new
formulations and formulation processes, thereby strongly adding to the value of
our clients' products."
About OctoPlus
OctoPlus is a leading European provider of advanced drug formulation and
clinical scale manufacturing services to the pharmaceutical and biotechnology
industries, with a focus on difficult to formulate active pharmaceutical
ingredients. OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the
symbol OCTO. For more information about OctoPlus, please visit our website
www.octoplus.nl.
In addition, OctoPlus is a specialty pharmaceutical company focused on the
development and manufacture of improved injectable pharmaceuticals based on our
proprietary drug delivery technologies that exhibit fewer side effects, improved
patient convenience and a better efficacy/safety balance than existing
therapies. OctoPlus also focuses on the development of long-acting, controlled
release versions of known protein therapeutics, peptides and small molecules,
including specialty generics.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate",
"predict",
"estimate", "project", "plan", "may",
"should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
Click here for the press release in PDF:
hugin.info/137076/R/1669124/542234.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
[HUG#1669124]
